IPCA Laboratories

IPCA Laboratories Operating Cash Flow

The Operating Cash Flow of IPCA Laboratories (IPCALAB.NS) as of Nov 4, 2026 is 11.42 B INR. In the previous year, Operating Cash Flow was 13.21 B INR — a change of -13.57% (lower).

Operating Cash Flow

11.42 BINR

YoY

-13.57%

Last updated:

Operating Cash Flow of IPCA Laboratories is 2026 11.42 B INR. Operating Cash Flow of IPCA Laboratories was 2025 13.21 B INR. It decreases by -13.57% lower compared to the previous year.

The IPCA Laboratories Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2019
5.01 B INR
Jan 1, 2020
5.70 B INR
Jan 1, 2021
10.90 B INR
Jan 1, 2022
8.56 B INR
Jan 1, 2023
8.06 B INR
Jan 1, 2024
10.21 B INR
Jan 1, 2025
13.21 B INR
Jan 1, 2026
11.42 B INR
The IPCA Laboratories Operating Cash Flow history
YEAROperating Cash FlowYoY
11.42 BINR-13.57%
13.21 BINR+29.40%
10.21 BINR+26.72%
8.06 BINR-5.87%
8.56 BINR-21.47%
10.90 BINR+91.13%
5.70 BINR+13.84%
5.01 BINR+46.87%
3.41 BINR+21.01%
2.82 BINR-60.22%
7.09 BINR+51.35%
4.68 BINR-10.35%
5.22 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IPCA Laboratories Stock analysis

What does IPCA Laboratories do? Ipca Laboratories Ltd. generates revenue through the manufacturing and marketing of over 350 pharmaceutical formulations and approximately 80 active pharmaceutical ingredients (APIs), including Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts, and Propranolol. The company sells its branded products such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, and Venpower in more than 100 countries globally. Its subsidiaries, Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd, and Tonira Exports Limited, support the distribution and sales of these products across international markets. The company's primary customers are healthcare providers, hospitals, and pharmacies in over 100 countries, purchasing both generic APIs and branded formulations. Manufacturing units in India produce APIs and formulations, with the firm's subsidiaries facilitating global market access. The therapeutic segments covered by its products include cardiovascular, antimalarial, and gastrointestinal treatments, among others, driven by the demand for cost-effective pharmaceutical solutions. IPCA Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IPCA Laboratories stock

Operating Cash Flow of IPCA Laboratories is 11.42 B INR in 2026.

Operating Cash Flow of IPCA Laboratories changed from 13.21 B INR to 11.42 B INR, representing a -13.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow IPCA Laboratories since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's IPCA Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — IPCA Laboratories

All Key Metrics — IPCA Laboratories